Cargando…

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

OBJECTIVES: Our initiative aimed to produce recommendations on post-randomised controlled trial (RCT) trial extension studies (TES) reporting using European League Against Rheumatism (EULAR) standard operating procedures in order to achieve more meaningful output and standardisation of reports. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Buch, Maya H, Silva-Fernandez, Lucia, Carmona, Loreto, Aletaha, Daniel, Christensen, Robin, Combe, Bernard, Emery, Paul, Ferraccioli, Gianfranco, Guillemin, Francis, Kvien, Tore K, Landewe, Robert, Pavelka, Karel, Saag, Kenneth, Smolen, Josef S, Symmons, Deborah, van der Heijde, Désirée, Welling, Joep, Wells, George, Westhovens, Rene, Zink, Angela, Boers, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431343/
https://www.ncbi.nlm.nih.gov/pubmed/24827533
http://dx.doi.org/10.1136/annrheumdis-2013-204948
_version_ 1782371329538785280
author Buch, Maya H
Silva-Fernandez, Lucia
Carmona, Loreto
Aletaha, Daniel
Christensen, Robin
Combe, Bernard
Emery, Paul
Ferraccioli, Gianfranco
Guillemin, Francis
Kvien, Tore K
Landewe, Robert
Pavelka, Karel
Saag, Kenneth
Smolen, Josef S
Symmons, Deborah
van der Heijde, Désirée
Welling, Joep
Wells, George
Westhovens, Rene
Zink, Angela
Boers, Maarten
author_facet Buch, Maya H
Silva-Fernandez, Lucia
Carmona, Loreto
Aletaha, Daniel
Christensen, Robin
Combe, Bernard
Emery, Paul
Ferraccioli, Gianfranco
Guillemin, Francis
Kvien, Tore K
Landewe, Robert
Pavelka, Karel
Saag, Kenneth
Smolen, Josef S
Symmons, Deborah
van der Heijde, Désirée
Welling, Joep
Wells, George
Westhovens, Rene
Zink, Angela
Boers, Maarten
author_sort Buch, Maya H
collection PubMed
description OBJECTIVES: Our initiative aimed to produce recommendations on post-randomised controlled trial (RCT) trial extension studies (TES) reporting using European League Against Rheumatism (EULAR) standard operating procedures in order to achieve more meaningful output and standardisation of reports. METHODS: We formed a task force of 22 participants comprising RCT experts, clinical epidemiologists and patient representatives. A two-stage Delphi survey was conducted to discuss the domains of evaluation of a TES and definitions. A ‘0–10’ agreement scale assessed each domain and definition. The resulting set of recommendations was further refined and a final vote taken for task force acceptance. RESULTS: Seven key domains and individual components were evaluated and led to agreed recommendations including definition of a TES (100% agreement), minimal data necessary (100% agreement), method of data analysis (agreement mean (SD) scores ranging between 7.9 (0.84) and 9.0 (2.16)) and reporting of results as well as ethical issues. Key recommendations included reporting of absolute numbers at each stage from the RCT to TES with reasons given for drop-out at each stage, and inclusion of a flowchart detailing change in numbers at each stage and focus (mean (SD) agreement 9.9 (0.36)). A final vote accepted the set of recommendations. CONCLUSIONS: This EULAR task force provides recommendations for implementation in future TES to ensure a standardised approach to reporting. Use of this document should provide the rheumatology community with a more accurate and meaningful output from future TES, enabling better understanding and more confident application in clinical practice towards improving patient outcomes.
format Online
Article
Text
id pubmed-4431343
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44313432015-05-15 Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology Buch, Maya H Silva-Fernandez, Lucia Carmona, Loreto Aletaha, Daniel Christensen, Robin Combe, Bernard Emery, Paul Ferraccioli, Gianfranco Guillemin, Francis Kvien, Tore K Landewe, Robert Pavelka, Karel Saag, Kenneth Smolen, Josef S Symmons, Deborah van der Heijde, Désirée Welling, Joep Wells, George Westhovens, Rene Zink, Angela Boers, Maarten Ann Rheum Dis Recommendation OBJECTIVES: Our initiative aimed to produce recommendations on post-randomised controlled trial (RCT) trial extension studies (TES) reporting using European League Against Rheumatism (EULAR) standard operating procedures in order to achieve more meaningful output and standardisation of reports. METHODS: We formed a task force of 22 participants comprising RCT experts, clinical epidemiologists and patient representatives. A two-stage Delphi survey was conducted to discuss the domains of evaluation of a TES and definitions. A ‘0–10’ agreement scale assessed each domain and definition. The resulting set of recommendations was further refined and a final vote taken for task force acceptance. RESULTS: Seven key domains and individual components were evaluated and led to agreed recommendations including definition of a TES (100% agreement), minimal data necessary (100% agreement), method of data analysis (agreement mean (SD) scores ranging between 7.9 (0.84) and 9.0 (2.16)) and reporting of results as well as ethical issues. Key recommendations included reporting of absolute numbers at each stage from the RCT to TES with reasons given for drop-out at each stage, and inclusion of a flowchart detailing change in numbers at each stage and focus (mean (SD) agreement 9.9 (0.36)). A final vote accepted the set of recommendations. CONCLUSIONS: This EULAR task force provides recommendations for implementation in future TES to ensure a standardised approach to reporting. Use of this document should provide the rheumatology community with a more accurate and meaningful output from future TES, enabling better understanding and more confident application in clinical practice towards improving patient outcomes. BMJ Publishing Group 2015-06 2014-05-14 /pmc/articles/PMC4431343/ /pubmed/24827533 http://dx.doi.org/10.1136/annrheumdis-2013-204948 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Recommendation
Buch, Maya H
Silva-Fernandez, Lucia
Carmona, Loreto
Aletaha, Daniel
Christensen, Robin
Combe, Bernard
Emery, Paul
Ferraccioli, Gianfranco
Guillemin, Francis
Kvien, Tore K
Landewe, Robert
Pavelka, Karel
Saag, Kenneth
Smolen, Josef S
Symmons, Deborah
van der Heijde, Désirée
Welling, Joep
Wells, George
Westhovens, Rene
Zink, Angela
Boers, Maarten
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title_full Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title_fullStr Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title_full_unstemmed Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title_short Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
title_sort development of eular recommendations for the reporting of clinical trial extension studies in rheumatology
topic Recommendation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431343/
https://www.ncbi.nlm.nih.gov/pubmed/24827533
http://dx.doi.org/10.1136/annrheumdis-2013-204948
work_keys_str_mv AT buchmayah developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT silvafernandezlucia developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT carmonaloreto developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT aletahadaniel developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT christensenrobin developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT combebernard developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT emerypaul developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT ferraccioligianfranco developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT guilleminfrancis developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT kvientorek developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT landewerobert developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT pavelkakarel developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT saagkenneth developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT smolenjosefs developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT symmonsdeborah developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT vanderheijdedesiree developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT wellingjoep developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT wellsgeorge developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT westhovensrene developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT zinkangela developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology
AT boersmaarten developmentofeularrecommendationsforthereportingofclinicaltrialextensionstudiesinrheumatology